Inpharma Weekly

, Volume 985, Issue 1, pp 11–12 | Cite as

Peptide-based EBV vaccine in phase I trial

  • Jo Barnes
Newsletter Article


The first clinical study of a synthetic peptide-based vaccine against the Epstein-Barr virus (EBV) is now underway. Researchers are hopeful that the vaccine, which contains a cytotoxic T-lymphocyte (CTL) epitope, may protect against EBV immunopathology. Inpharma spoke to Dr Andreas Suhrbier, from the Queensland Institute of Medical Research, Brisbane, Australia, about the current phase I trial and the potential applications for an EBV vaccine in protecting against infectious mononucleosis (glandular fever) and the development of post-transplant lymphoproliferative disease (PTLD).


Tetanus Toxoid Latent Membrane Protein Infectious Mononucleosis MCMV Infection Peptide Component 

Copyright information

© Adis International Ltd 1995

Authors and Affiliations

  • Jo Barnes

There are no affiliations available

Personalised recommendations